Generic drug company Apotex Inc. said Tuesday an arbitration tribunal has rejected its claims that the U.S. Food and Drug Administration violated the North American Free Trade Agreement by prohibiting imports of Apotex products from two Ontario plants for nearly two years.
Apotex president and chief executive Jeremy Desai said the company was disappointed by the decision. […]
The U.S. Food and Drug Administration placed an import alert on two Apotex plants in Ontario on Aug. 28, 2009, that prevented the shipment of drugs they produced to the U.S. The alert followed concerns raised by FDA inspections of the plants, however, Apotex accused the U.S. regulator of treating U.S. companies more favourably in similar circumstances. Read more here.